Literature DB >> 19068482

Two arginine-glutamate ionic locks near the extracellular surface of FFAR1 gate receptor activation.

Chi Shing Sum1, Irina G Tikhonova, Stefano Costanzi, Marvin C Gershengorn.   

Abstract

Activation of a number of class A G protein-coupled receptors (GPCRs) is thought to involve two molecular switches, a rotamer toggle switch within the transmembrane domain and an ionic lock at the cytoplasmic surface of the receptor; however, the mechanism by which agonist binding changes these molecular interactions is not understood. Importantly, 80% of GPCRs including free fatty acid receptor 1 (FFAR1) lack the complement of amino acid residues implicated in either or both of these two switches; the mechanism of activation of these GPCRs is therefore less clear. By homology modeling, we identified two Glu residues (Glu-145 and Glu-172) in the second extracellular loop of FFAR1 that form putative interactions individually with two transmembrane Arg residues (Arg-183(5.39) and Arg-258(7.35)) to create two ionic locks. Molecular dynamics simulations showed that binding of agonists to FFAR1 leads to breakage of these Glu-Arg interactions. In mutagenesis experiments, breakage of these two putative interactions by substituting Ala for Glu-145 and Glu-172 caused constitutive receptor activation. Our results therefore reveal a molecular switch for receptor activation present on the extracellular surface of FFAR1 that is broken by agonist binding. Similar ionic locks between the transmembrane domains and the extracellular loops may constitute a mechanism common to other class A GPCRs also.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19068482      PMCID: PMC2635034          DOI: 10.1074/jbc.M806987200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  42 in total

1.  Crystal structure of rhodopsin: A G protein-coupled receptor.

Authors:  K Palczewski; T Kumasaka; T Hori; C A Behnke; H Motoshima; B A Fox; I Le Trong; D C Teller; T Okada; R E Stenkamp; M Yamamoto; M Miyano
Journal:  Science       Date:  2000-08-04       Impact factor: 47.728

Review 2.  A2A adenosine receptor and its modulators: overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists.

Authors:  G Cristalli; C Lambertucci; G Marucci; R Volpini; D Dal Ben
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

3.  Evidence for a model of agonist-induced activation of 5-hydroxytryptamine 2A serotonin receptors that involves the disruption of a strong ionic interaction between helices 3 and 6.

Authors:  David A Shapiro; Kurt Kristiansen; David M Weiner; Wesley K Kroeze; Bryan L Roth
Journal:  J Biol Chem       Date:  2002-01-18       Impact factor: 5.157

Review 4.  Seven transmembrane-spanning receptors for free fatty acids as therapeutic targets for diabetes mellitus: pharmacological, phylogenetic, and drug discovery aspects.

Authors:  Stefano Costanzi; Susanne Neumann; Marvin C Gershengorn
Journal:  J Biol Chem       Date:  2008-04-02       Impact factor: 5.157

5.  Activation of the beta 2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6.

Authors:  J A Ballesteros; A D Jensen; G Liapakis; S G Rasmussen; L Shi; U Gether; J A Javitch
Journal:  J Biol Chem       Date:  2001-05-25       Impact factor: 5.157

6.  Toward deciphering the code to aminergic G protein-coupled receptor drug design.

Authors:  Edwin S Tan; Eli S Groban; Matthew P Jacobson; Thomas S Scanlan
Journal:  Chem Biol       Date:  2008-04

7.  On the applicability of GPCR homology models to computer-aided drug discovery: a comparison between in silico and crystal structures of the beta2-adrenergic receptor.

Authors:  Stefano Costanzi
Journal:  J Med Chem       Date:  2008-04-29       Impact factor: 7.446

8.  Discovery of novel agonists and antagonists of the free fatty acid receptor 1 (FFAR1) using virtual screening.

Authors:  Irina G Tikhonova; Chi Shing Sum; Susanne Neumann; Stanislav Engel; Bruce M Raaka; Stefano Costanzi; Marvin C Gershengorn
Journal:  J Med Chem       Date:  2008-01-15       Impact factor: 7.446

Review 9.  G-protein-coupled receptors and islet function-implications for treatment of type 2 diabetes.

Authors:  Maria Sörhede Winzell; Bo Ahrén
Journal:  Pharmacol Ther       Date:  2007-08-29       Impact factor: 12.310

10.  Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice.

Authors:  Carina P Tan; Yue Feng; Yun-Ping Zhou; George J Eiermann; Aleksandr Petrov; Changyou Zhou; Songnian Lin; Gino Salituro; Peter Meinke; Ralph Mosley; Taro E Akiyama; Monica Einstein; Sanjeev Kumar; Joel P Berger; Sander G Mills; Nancy A Thornberry; Lihu Yang; Andrew D Howard
Journal:  Diabetes       Date:  2008-05-13       Impact factor: 9.461

View more
  25 in total

1.  Comparison of dynamics of extracellular accesses to the β(1) and β(2) adrenoceptors binding sites uncovers the potential of kinetic basis of antagonist selectivity.

Authors:  Balaji Selvam; Jeff Wereszczynski; Irina G Tikhonova
Journal:  Chem Biol Drug Des       Date:  2012-05-02       Impact factor: 2.817

2.  Extracellular loop 2 of the free fatty acid receptor 2 mediates allosterism of a phenylacetamide ago-allosteric modulator.

Authors:  Nicola J Smith; Richard J Ward; Leigh A Stoddart; Brian D Hudson; Evi Kostenis; Trond Ulven; Joanne C Morris; Christian Tränkle; Irina G Tikhonova; David R Adams; Graeme Milligan
Journal:  Mol Pharmacol       Date:  2011-04-15       Impact factor: 4.436

Review 3.  Lifting the lid on GPCRs: the role of extracellular loops.

Authors:  M Wheatley; D Wootten; M T Conner; J Simms; R Kendrick; R T Logan; D R Poyner; J Barwell
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

4.  Free fatty acid receptors: emerging targets for treatment of diabetes and its complications.

Authors:  Venkat Vangaveti; Venkatesh Shashidhar; Ghassan Jarrod; Bernhard T Baune; R Lee Kennedy
Journal:  Ther Adv Endocrinol Metab       Date:  2010-08       Impact factor: 3.565

5.  High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875.

Authors:  Ankita Srivastava; Jason Yano; Yoshihiko Hirozane; Georgia Kefala; Franz Gruswitz; Gyorgy Snell; Weston Lane; Anthony Ivetac; Kathleen Aertgeerts; Jasmine Nguyen; Andy Jennings; Kengo Okada
Journal:  Nature       Date:  2014-07-20       Impact factor: 49.962

Review 6.  Rhodopsin and the others: a historical perspective on structural studies of G protein-coupled receptors.

Authors:  Stefano Costanzi; Jeffrey Siegel; Irina G Tikhonova; Kenneth A Jacobson
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

7.  Signaling-sensitive amino acids surround the allosteric ligand binding site of the thyrotropin receptor.

Authors:  Gunnar Kleinau; Ann-Karin Haas; Susanne Neumann; Catherine L Worth; Inna Hoyer; Jens Furkert; Claudia Rutz; Marvin C Gershengorn; Ralf Schülein; Gerd Krause
Journal:  FASEB J       Date:  2010-02-23       Impact factor: 5.191

Review 8.  Agonism and allosterism: the pharmacology of the free fatty acid receptors FFA2 and FFA3.

Authors:  Graeme Milligan; Leigh A Stoddart; Nicola J Smith
Journal:  Br J Pharmacol       Date:  2009-09       Impact factor: 8.739

9.  The action and mode of binding of thiazolidinedione ligands at free fatty acid receptor 1.

Authors:  Nicola J Smith; Leigh A Stoddart; Nicola M Devine; Laura Jenkins; Graeme Milligan
Journal:  J Biol Chem       Date:  2009-04-27       Impact factor: 5.157

Review 10.  Molecular mechanisms of target recognition by lipid GPCRs: relevance for cancer.

Authors:  M T M van Jaarsveld; J M Houthuijzen; E E Voest
Journal:  Oncogene       Date:  2015-12-07       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.